BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home
»
Newsletters
» BioWorld
BioWorld
April 28, 2008
View Archived Issues
Astellas, CoMentis in $760M Deal for Alzheimer's Treatment
Japanese drugmaker Astellas Pharma Inc. is partnering with CoMentis Inc. to develop a compound for Alzheimer's disease under a deal potentially worth $760 million for the latter. (BioWorld Today)
Read More
FDA OKs Progenics Drug; EMA also Gives It a Nod
Read More
Japan Pharmas' Love for U.S. Biotechs Just Heating Up
Read More
Observational Trials Have Merits, but Stark Limits also Apparent
Read More
Amgen Posts Flat 1st Quarter, as Future Hinges on Denosumab
Read More
Isis Shares Slip on Need for Mipomersen Data
Read More
House Measure Reauthorizes BIO-Backed SBIR Grants
Read More
Other News To Note
Read More
Clinic Roundup
Read More
